Release date: 2012-09-26 Source: China Medical Technology Network Sealing Profiles,Edge Sealing Profiles,Clip On Sealing Profiles,Channel Sealing Profiles Ningbo Hengchieh Locking Technology Co., Ltd. , https://www.hengchieh.com
Recently, the National Cardiovascular Center Fuwai Hospital held a press conference to report the first two patients with severe aortic stenosis who could not undergo surgical treatment. The Chinese aortic valve device was placed in a "open chest" manner. .
Previously, there was no aortic valve placed by catheter in China, and there was no clinical research for Chinese people. Hu Shengshou, dean of Fuwai Hospital and director of the National Cardiovascular Center, evaluated the achievement as a milestone in China's translational medicine and a typical success model for the national 863 project to support small and medium-sized enterprises.
The "fourth revolution" in the field of cardiovascular intervention
Academician Gao Runlin of the National Cardiovascular Center said that there are four valves in the heart. As people age, many elderly people will have calcification in the heart, which will inevitably cause aortic stenosis, which will cause cardiac output. Down, the symptoms are chest tightness, shortness of breath, angina, and even sudden death.
Professor Yang Yuejin from the National Cardiovascular Center pointed out that China's population aging trend is obvious, cardiovascular risk factors are prevalent, and patients with valvular degenerative diseases are increasing year by year. According to foreign data, valvular disease occurs in 2% to 7% of elderly people older than 65 years.
In the past, severe aortic stenosis was only treated with surgical valve replacement surgery. However, in advanced patients, serious diseases involving other system organs were not able to tolerate surgery, and the treatment was lost. The drug treatment was poor and the mortality rate was extremely high. .
Europe and the United States have been advancing transcatheter aortic valves since 2002. This technology is known as the fourth revolution in the field of cardiovascular intervention. According to a randomized controlled trial of foreign patients with severe aortic stenosis who are unable to undergo surgical valve replacement surgery, transcatheter aortic valve placement has a 46% reduction in the risk of death per year compared to standard treatment (decreased absolute mortality) 20%).
Since the first transcatheter aortic valve placement in France in 2002, more than 50,000 patients worldwide have benefited from this treatment.
The successful model of the National 863 Project The aortic valve required for catheterization is now only the same kind of products produced by Medtronic and Edwards in foreign countries. It is expensive and has not entered the Chinese market.
The device that was placed this time is the Venus A-Valve? produced by Hangzhou Qiming Medical Co., Ltd., which is a self-expanding biofilm leaf.
According to the academician Gao Runlin of the National Cardiovascular Center, the domestic valve is more reasonable in design and easier to operate. In addition, during operation, once the position is found to be offset, it can be recovered and repositioned. It is the first retractable catheter valve system for clinical use.
Qiming Medical, which developed the valve, is the industrial unit of the National 863 Valve Project. It has been supported by the National SME Innovation Fund with high scores. During the development of the valve, it communicated with experts from Fuwai Hospital. More than 60 adjustments and improvements.
"The successful development of Venus valve and its clinical trials is a result of China's vigorous promotion of the combination of production, education and research, and promotion of scientific and technological innovation policies. It is also a successful model in the 863 project of the Ministry of Science and Technology of China." Dean Hu Shengshou commented.